

Thank you for Subscribing to Cannabis Business Insights Weekly Brief
Maribelle Guloy is the Director of Clinical Development at American Regent, a company of Daiichi Sankyo. Before joining American Regent, Dr. Guloy held various full-time and consulting roles at CROs, pharmaceutical, and biotech companies, including Moderna.
Dr. Guloy is an active member of the professional community. She serves on the Advisory Board of the University of California, Irvine (UCI) Clinical Trials, Medical Device, and Drug Development program and UCI’s Beall Innovation program. She has also served on the Board of Directors for the Society of Clinical Research Associates, Inc. Dr. Guloy earned her Doctor of Health Science in Global Health from Nova Southeastern University in Florida, her Master of Science in Health Science and Clinical Research Administration from George Washington University in Washington, DC, and her Bachelor of Science in Medical Technology from the University of Immaculate Conception in the Philippines. From Milestones to Mastery My journey in clinical development began in 2000 when I cofounded and managed an oncology-focused clinical research organization (CRO) for 16 years. Working in a smaller company provided me with the flexibility and opportunity to pursue my master’s and doctoral degrees, with a vision to transition into the clinical science and drug research & development space. In 2007, I joined the University of California Irvine’s (UCI) Life Science and Engineering department as an Advisory Board member, a role that later expanded into being an Innovation Advisor within UCI’s Beall Applied Innovation program. I also served on the Board of Directors at the Society of Clinical Research Associates, Inc. My career has included leadership and consulting positions at various CROs, pharmaceutical, and biotech companies such as Moderna. In 2022, I joined American Regent following its acquisition of HBT Labs, where I had been working. Each step in my career has built on the last, shaping my expertise and passion for advancing clinical development. Overcoming Challenges for Sustainable Clinical Development Clinical development is rife with challenges, including regulatory hurdles and recruitment difficulties, often leading to trial delays and increased costs. To address these obstacles, I prioritized close engagement with regulatory agencies to secure guidance and consensus on development plans. Taking clinical trials outside the U.S. with a well-structured outsourcing plan and robust quality oversight processes proved an effective strategy.Clinical development is the backbone of translating research into treatments. By forging pathways for pipeline advancements, we contribute to transforming healthcare with innovative treatments that address unmet patient needs and enhance lives
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info